Clinical characteristics and treatment of perianal fistulising Crohn's disease in Colombia: Results of a multicentric registry.
Características clínicas y tratamiento de la enfermedad de Crohn perianal fistulizante en Colombia: resultados de un registro multicéntrico.
Biological therapy
Crohn's disease
Enfermedad de Crohn
Fistula perianal
Perianal fistula
Setones
Setons
Terapia biológica
Journal
Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
16
01
2022
revised:
22
02
2022
accepted:
28
02
2022
pubmed:
13
3
2022
medline:
9
11
2022
entrez:
12
3
2022
Statut:
ppublish
Résumé
Perianal fistulizing Crohn's disease (CD) is a phenotype with a poor prognosis. There are no studies in our country. Our objective is to determine the clinical, sociodemographic and treatment characteristics of perianal fistulizing CD in a Colombian multicenter registry. A retrospective, multicenter observational study was carried out, with prospective data collection, in the main reference centers for inflammatory Bowel disease (IBD) in the country. Continuous variables were expressed as medians and interquartile ranges. The categorical outcome variables were compared by the Chi-square test. Sixty-five patients with perianal fistulizing CD were documented, with a median age of appearance of perianal fistula of 31.0 years (range: 24-42), predominantly in men (61.5%; H:M ratio: 1.4:1). Complex perianal fistulas were more frequent than simple ones (75.35 vs. 24.6%). Regarding medical treatment, 66.2% of the patients received antibiotics, 64.6% steroids, 78.5% biological therapy, 47.7% non-cutting setons, and 46.2% required surgical management, other than seton placement. Only 29.2% achieved complete remission of the fistula, and 9.2% of the patients ended up in a definitive colostomy. CD patients with complex fistulas received more biological therapy, compared to CD patients with simple fistulas (84.8 vs. 56.3%; P: 0.038). Perianal fistulizing CD has a poor prognosis in our setting, only 3 out of 10 patients achieve complete remission despite treatment. A multidisciplinary management is essential for the comprehensive management of this difficult pathology.
Identifiants
pubmed: 35278506
pii: S0210-5705(22)00083-8
doi: 10.1016/j.gastrohep.2022.02.006
pii:
doi:
Substances chimiques
Infliximab
B72HH48FLU
Antibodies, Monoclonal
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
690-696Informations de copyright
Copyright © 2022 Elsevier España, S.L.U. All rights reserved.